×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Dr. Christianson is a naturopathic medical doctor and the author of four books, including his latest, The Adrenal Reset Diet. He is based in Scottsdale, Ariz., where he founded Integrative Health, a physician group dedicated to helping people with thyroid disease and weight-loss resistance. He regularly appears on national TV shows, including Today and The Doctors. His website is at www.drchristianson.com
Tags: GOV | HEA | INDUSTRIES | NORTHAM | TOP | US | WORLD

US-Run Trial of Eli Lilly Antibody Therapy for COVID to End

US-Run Trial of Eli Lilly Antibody Therapy for COVID to End
(Dreamstime)

Monday, 26 October 2020 06:56 PM

Eli Lilly & Co. said a clinical trial of its experimental antibody therapy in hospitalized Covid-19 patients will end, after the U.S. government-run study was paused earlier this month.

The company said in a statement that the decision was based on data suggesting the treatment is unlikely to help hospitalized Covid-19 patients recover from the advanced stage of their disease.

On Oct. 14, the Indianapolis drug giant said enrollment had been paused in the so-called ACTIV-3 trial of its neutralizing monoclonal antibody treatment sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

The NIH said in a statement on Monday that Lilly’s drug is likely to be ineffective in treating hospitalized patients.

The announcement is an indication that monoclonal antibodies for Covid-19 may only work if given early in the course of a coronavirus infection, before the virus has had a chance to penetrate deep into the lungs and cause serious damage. In the study, a very high dose of Lilly’s antibody was used, yet there was no indication that it was effective.

Earlier in October, the trial’s data-safety monitors recommend the pause, but didn’t recommend pausing another government-run trial, known as ACTIV-2. That trial is continuing, Lilly said, and company-sponsored studies of the antibody therapy also continued unaffected.

ACTIV-3 was testing a high-dose version of the antibody treatment Lilly is developing with Canadian biotech AbCellera Biologics Inc. in combination with the antiviral drug remdesivir. The study had already enrolled 326 participants who were hospitalized with Covid-19.

Eli Lilly is seeking emergency authorization to treat coronavirus patients outside of the hospital with the antibody outside of the hospital. In contrast to the hospital trial results, a trial in this group of patients has produced promising results in September.

© Copyright 2021 Bloomberg News. All rights reserved.


US
Eli Lilly & Co. said a clinical trial of its experimental antibody therapy in hospitalized Covid-19 patients will end, after the U.S. government-run study was paused earlier this month. The company said in a statement that the decision was based on data suggesting the...
GOV, HEA, INDUSTRIES, NORTHAM, TOP, US, WORLD, WWTOP, WWTOPAM
296
2020-56-26
Monday, 26 October 2020 06:56 PM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved